# Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC

> **NCT04865250** · PHASE2 · RECRUITING · sponsor: **University Hospital Heidelberg** · enrollment: 20 (estimated)

## Conditions studied

- NSCLC Stage II
- NSCLC, Stage IIIA
- NSCLC Stage IIIB

## Interventions

- **DRUG:** Atezolizumab 1200 mg abs day 1 q22 (iv)

## Key facts

- **NCT ID:** NCT04865250
- **Lead sponsor:** University Hospital Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-07
- **Primary completion:** 2024-11-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04865250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04865250, "Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04865250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*